CCM
MRNA icon

Coldstream Capital Management’s Moderna MRNA Stock Holding History

Coldstream Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$450K Buy
8,859
+944
+12% +$44K 0.01% 769
2025
Q4 		$233K Sell
7,915
-1,610
-17% -$43.7K ﹤0.01% 1026
2025
Q3 		$246K Buy
9,525
+2,272
+31% +$63.4K ﹤0.01% 1037
2025
Q2 		$200K Buy
7,253
+2,039
+39% +$53.7K ﹤0.01% 1072
2025
Q1 		$148K Buy
5,214
+165
+3% +$5.86K ﹤0.01% 1155
2024
Q4 		$210K Buy
5,049
+1,440
+40% +$68.8K ﹤0.01% 991
2024
Q3 		$236K Sell
3,609
-745
-17% -$68.4K 0.01% 963
2024
Q2 		$517K Buy
4,354
+1,011
+30% +$128K 0.01% 536
2024
Q1 		$356K Buy
3,343
+675
+25% +$68K 0.01% 689
2023
Q4 		$265K Sell
2,668
-867
-25% -$72.9K 0.01% 758
2023
Q3 		$365K Buy
3,535
+77
+2% +$8.59K 0.01% 542
2023
Q2 		$420K Sell
3,458
-251
-7% -$33.5K 0.01% 503
2023
Q1 		$570K Sell
3,709
-465
-11% -$76.7K 0.02% 395
2022
Q4 		$750K Buy
+4,174
New +$682K 0.03% 317
2022
Q2 		$496K Buy
3,469
+638
+23% +$91.2K 0.02% 392
2022
Q1 		$488K Buy
2,831
+49
+2% +$8.25K 0.02% 393
2021
Q4 		$707K Buy
+2,782
New +$813K 0.02% 309
2021
Q3 		– Sell
-1,209
Closed -$284K – 496
2021
Q2 		$284K Buy
+1,209
New +$216K 0.01% 403

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coldstream Capital Management's MRNA Position: Q1 2026 in Review

Coldstream Capital Management increased its Moderna (MRNA) stake by 12% in Q1 2026, buying an estimated $44K and bringing the position to 8,859 shares worth $450K. The position accounts for 0.01% of the portfolio, ranked #769.

Coldstream Capital Management first reported a position in MRNA in Q2 2021 and has held it in 18 quarters since. The position peaked at $750K in Q4 2022. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Coldstream Capital Management held 8,859 shares of Moderna worth $450K as of Q1 2026.
  • Coldstream Capital Management bought 944 Moderna shares in Q1 2026, an estimated $44K.
  • Moderna made up 0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #769 holding.
  • Coldstream Capital Management first reported a position in Moderna in Q2 2021 and has held it in 18 quarters since.
  • Coldstream Capital Management's Moderna position peaked at $750K in Q4 2022.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.